NEW YORK (GenomeWeb News) - Genomic Health is using Tecan’s liquid-handling workstations to automate the developmental process for its cancer recurrence assays, Tecan said this week.
Genomic Health markets Oncotype DX, a gene expression assay that predicts the risk of recurrence of cancer and the likelihood of chemotherapy benefit in early-stage breast cancer patients.
Genomic Health’s director of process automation, Jay Snable, said the company is using the Tecan technology as part of a new project that is studying 761 genes “in an initial screen to create a gene profile for an assay to test for risk of recurrence of another cancer type.”
The company is using Tecan’s Freedom EVO 200 and Genesis platforms to automate all assay steps after RNA extraction, including RNA quantification and quality control, reverse transcription, and quantitative PCR assay assembly.
The workstations are also equipped with Tecan’s PosID barcode-scanning system, Tecan said.
Financial terms of the agreement were not released.